Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Our investment areas of focus are new products and technologies for oncology, immunology, neurology, and rare disease indications. We make direct equity investments across all stages of development and types of financing rounds.

Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Our investment areas of focus are new products and technologies for oncology, immunology, neurology and rare disease indications. We make direct equity investments across all stages of development and types of financing rounds.

Aptinyx

Dice Therapeutics

Entrada Therapeutics

Orchard Therapeutics

Pliant Therapeutics

Precision BioSciences

Pyxis Oncology

Agent Capital

We are excited for Eli Lilly and Company to acquire our portfolio company, DICE Therapeutics. Congratulations to the entire DICE Therapeutics team and  Kevin Judice for their dedication! Agent Capital is honored to have been part of this exciting journey, and we look forward to DICE Therapeutics’ next chapter as a part of Eli Lilly and Company to accelerate the development of novel oral therapeutics to treat autoimmune diseases.

Read more: https://bit.ly/3CCfhzE

Congratulations to the Pyxis Oncology team on this milestone!

Congratulations to Cyrus Biotechnology's scientist, Erik Procko, and the company's lead ACE2-Fc Fusion protein COVID-19 therapeutic for being featured in Science news article!
https://lnkd.in/gGkF8iWD

COM:AGENTCAPITAL

Agent Capital

Analysis Not Available